T3X Stock Overview
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Telix Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$14.35 |
| 52 Week High | AU$26.00 |
| 52 Week Low | AU$9.60 |
| Beta | 2.38 |
| 1 Month Change | -2.48% |
| 3 Month Change | -10.93% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 19.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| T3X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.7% | -1.3% | 1.2% |
| 1Y | n/a | -13.3% | 14.0% |
Return vs Industry: Insufficient data to determine how T3X performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how T3X performed against the German Market.
Price Volatility
| T3X volatility | |
|---|---|
| T3X Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: T3X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: T3X's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 423 | Chris Behrenbruch | telixpharma.com |
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma.
Telix Pharmaceuticals Limited Fundamentals Summary
| T3X fundamental statistics | |
|---|---|
| Market cap | €4.87b |
| Earnings (TTM) | €28.59m |
| Revenue (TTM) | €448.59m |
170.2x
P/E Ratio10.8x
P/S RatioIs T3X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| T3X income statement (TTM) | |
|---|---|
| Revenue | AU$783.21m |
| Cost of Revenue | AU$299.26m |
| Gross Profit | AU$483.95m |
| Other Expenses | AU$434.03m |
| Earnings | AU$49.92m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 61.79% |
| Net Profit Margin | 6.37% |
| Debt/Equity Ratio | 100.5% |
How did T3X perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/15 11:22 |
| End of Day Share Price | 2025/05/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Telix Pharmaceuticals Limited is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | Barclay Pearce Capital Pty Limited |
| John Hester | Bell Potter |
| Andrew Paine | CLSA |